There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Argenx Se (ARGX – Research Report), CVRx (CVRX – Research Report) and Capricor Therapeutics (CAPR – Research Report) with bullish sentiments.
Argenx Se (ARGX)
Piper Sandler analyst Allison Bratzel maintained a Buy rating on Argenx Se today and set a price target of $522.00. The company’s shares closed last Thursday at $382.54.
According to TipRanks.com, Bratzel is a 4-star analyst with an average return of
Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $479.47, a 28.9% upside from current levels. In a report issued on January 17, Wells Fargo also maintained a Buy rating on the stock with a $472.00 price target.
See today’s best-performing stocks on TipRanks >>
CVRx (CVRX)
In a report released today, Matthew O’Brien from Piper Sandler reiterated a Buy rating on CVRx, with a price target of $33.00. The company’s shares closed last Thursday at $29.20, close to its 52-week high of $33.14.
According to TipRanks.com, O’Brien is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CVRx with a $32.50 average price target, implying a 12.2% upside from current levels. In a report issued on January 22, Canaccord Genuity also maintained a Buy rating on the stock with a $31.00 price target.
Capricor Therapeutics (CAPR)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Capricor Therapeutics, with a price target of $12.00. The company’s shares closed last Thursday at $4.10.
According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Capricor Therapeutics with a $20.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARGX:
- Argenx downgraded to Hold from Buy at Kepler Cheuvreux
- Argenx price target raised to $518 from $515 at Piper Sandler
- Argenx announces MHLW approval for Vyvdura injection in Japan
- argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
- Argenx sees Q4 revenue $374M, consensus $358.94M
